Cabaletta Bio, Inc. CABA
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2019 · data as of November 13, 2026
Cabaletta Bio, Inc. (CABA) is a healthcare company listed in the US with a market value of about $276M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -55%.
About Cabaletta Bio
Cabaletta Bio is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2019. It was profitable in 0 of the last 8 years in our data. Its share count rose by 1245% over three years (dilution for shareholders).
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 8 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Net income | -$168M | -$116M | -$68M | -$53M | -$46M | -$33M | -$17M | -$12M |
| Free cash flow | -$132M | -$90M | -$54M | -$49M | -$35M | -$27M | -$17M | — |
| EPS (diluted) | $-2.10 | $-2.34 | $-1.65 | $-1.81 | $-1.80 | $-1.44 | $-4.07 | $-6.87 |
| Net margin | — | — | — | — | — | — | — | — |
| ROIC | -117.8% | -62.3% | -24.4% | -40.3% | -31.0% | -24.4% | -10.7% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 8 analysts is $11.75, 818% above the current price; targets range from $3.00 to $20.00; the consensus rating is “Strong buy”; expected EPS is $-1.29 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Cabaletta Bio pay a dividend?
Not currently.
Is Cabaletta Bio a good stock to buy?
We do not give buy or sell advice. Cabaletta Bio scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.